Tenderwize
Wróć do wyszukiwania

Open-House Supply Agreement for Therapy Allergens for Subcutaneous Immunotherapy

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Mar 03, 2028 · 553 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Therapie-Allergene zur subkutanen Immuntherapie, ATC V01AA02

62/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

62 / 100

Złożoność

48 / 100

Czynniki ryzyka

Contract documents must be submitted through the DTVP communications area and not through the offer area; using the wro...

Participation is limited to pharmaceutical companies and requires a signed reliability declaration; missing this would...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Non-exclusive open-house supply arrangement for therapy allergens for subcutaneous immunotherapy (ATC V01AA02).
  • Contract terms are pre-set and not individually negotiable.
Pokaż pełne podsumowanie

This is an open-house supply arrangement by AOK Bayern for pharmaceutical products (therapy allergens for subcutaneous immunotherapy, ATC V01AA02). It is explicitly described as not a standard competitive procurement, with identical non-exclusive contracts offered to all interested pharmaceutical companies meeting the stated suitability requirement. No contract value is provided. Submission is through DTVP or by paper originals in duplicate, with bilingual constraint to German and mandatory German translation for non-German documents. The notice is highly specific on contract start/end timing and monthly cut-off dates.

Ryzyka

Contract documents must be submitted through the DTVP communications area and not through the offer area; using the wro...

Participation is limited to pharmaceutical companies and requires a signed reliability declaration; missing this would...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Eligibility

  • Only pharmaceutical companies are eligible as potential contractual partners.

Administrative

  • Submit a signed reliability self-declaration.
  • Submit the signed contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open-House Supply Agreement for Therapy Allergens for Subcutaneous Immunotherapy

Open-house non-exclusive supply contract for therapy allergens for subcutaneous immunotherapy (ATC V01AA02). Scope is defined in the contract and related annexes downloadable from the tender documents. The notice says only pharmaceutical companies may become contractual partners. Lot information is from structured data and notice text.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Apr 2026 - Apr 2028

Kategoria

Pharmaceutical products

Termin

Deadline Mar 03, 2028

Szczegóły zamówienia

Data publikacji
15 Mar 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
179863-2026

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30